Catgut Implantation at Acupoints for the Treatment of Simple Obesity

December 3, 2019 updated by: Hubei Hospital of Traditional Chinese Medicine

Clinical Effect of Catgut Implantation at Acupoints for the Treatment of Simple Obesity: a Multicentre Randomized Controlled Trial

The primary objective of this multicenter randomized controlled trial is to evaluate treatment effectiveness of intervening simple obesity people with catgut implantation at preferred acupoints, which excludes placebo effect; the secondary objective is to evaluate safety and superiority of treating simple obesity with catgut implantation at acupoints to provide high-level evidence for it clinically.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This randomized, double-blind sham-controlled clinical trial will be conducted at Hubei Provincial Hospital of TCM, Dongzhimen Hospital Beijing University of Chinese Medicine and the First Hospital of Hunan University of Chinese Medicine. This study includes the following time points: a treatment period of 16 weeks after screening and a follow-up period of 24 weeks. The total study period will be 40 weeks. All patients will be randomized into the real catgut implantation at acupoints group or the sham catgut implantation at acupoints group.The primary outcome measurement of this study is the rate of waistline reduction compared with baseline. The secondary outcome measurements are the rate of reduction of weight, BMI, hipline, WHR and PBF, and changes in the IWQOL-Lite compared with baseline. These parameters will be evaluated at week 0, week 4, week 8, week 12, week 16, week 28 and week 40. Changes in SF-36, HAD and SES compared with baseline will be evaluated at week 0, week 16 and week 40. SF-36 and IWQOL-Lite will be used to evaluate obese patient quality of life. HAD and SES will be used to evaluate psychological status. In addition, hepatorenal function, blood fat, liver bladder spleen colour ultrasound, FBG and insulin concentration will be used to evaluate whether catgut implantation at acupoints can improve the physiological function of obese patients.

Study Type

Interventional

Enrollment (Actual)

216

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430061
        • Hubei Provincial Hospital of Traditional Chinese Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

Patients recruited for this study should meet the following inclusion criteria:

  1. meeting the diagnosis standard for simple obesity in Redefinition and Processing of Obesity in Asia & Pacific Area released by WHO in February 2000;
  2. age: 18-45;
  3. BMI: 25≤BMI<30;
  4. waistline: males ≥95 cm; females ≥85 cm;
  5. smokers have not changed their smoking habits for at least 2 months;
  6. willing to accept the above-described intervention methods.

Exclusion criteria

Patients with any of the following criteria will be excluded from the study:

  1. endocrine disease (such as polycystic ovarian syndrome, Cushing's Disease, and hypothyroidism, among others);
  2. gestational diabetes or uncontrolled hypertension (SBP ≥160 mmHg; DBP ≥100 mmHg) [23], or lung, heart, liver or kidney disease;
  3. nervous system disease or mental disorders, history of hospitalized depression, two instances of paralepsy or suicidal tendency;
  4. history of clinical diagnosis of an eating disorder , such as bulimia or cynorexia, anorexia; or weight changes greater than 5 kg in the previous 3 months;
  5. history of weight loss with surgery or a history of post-operative adhesion;
  6. having taken drugs with a known influence on weight or appetite in the previous 3 months, such as diet pills, corticosteroid drugs, anti-depression drugs, diazepam drugs, nonselective body antihistamine, nicotine replacements, or hypoglycaemic drugs, or planning to give up smoking and drinking;
  7. pregnancy, lactation, or planning to become pregnant within 40 weeks;
  8. received catgut implantation at acupoints;
  9. participated in clinical research on obesity in the previous 3 months ;
  10. protein allergy and scars;
  11. skin disease such as eczema and psoriasis;
  12. coagulation disorders, taking warfarin, heparin or other anticoagulant drugs;
  13. not cooperative or cannot maintain treatment during the study period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Real catgut implantation
Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
Device: Real catgut implantation at acupoints
  1. Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.
  2. lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week .
Sham Comparator: sham catgut implantation
Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
Device: sham catgut implantation at acupoints

Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.

lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
the rate of waistline reduction compared with baseline
Time Frame: week4 ,week8,week12,week16,week28,week40.
week4 ,week8,week12,week16,week28,week40.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the rate of reduction of weight compared with baseline
Time Frame: week4 ,week8,week12,week16,week28,week40.
week4 ,week8,week12,week16,week28,week40.
the rate of reduction of body mass index compared with baseline
Time Frame: week4 ,week8,week12,week16,week28,week40.
week4 ,week8,week12,week16,week28,week40.
the rate of reduction of hipline compared with baseline
Time Frame: week4 ,week8,week12,week16,week28,week40.
week4 ,week8,week12,week16,week28,week40.
the rate of reduction of waist-hip ratio compared with baseline
Time Frame: week4 ,week8,week12,week16,week28,week40.
week4 ,week8,week12,week16,week28,week40.
the rate of reduction of percentage of body fat compared with baseline
Time Frame: week4 ,week8,week12,week16,week28,week40.
week4 ,week8,week12,week16,week28,week40.
changes in IWQOL - Lite scale score compared with baseline
Time Frame: week4 ,week8,week12,week16,week28,week40.
week4 ,week8,week12,week16,week28,week40.
changes in SF - 36 life quality scale score compared with baseline
Time Frame: week4 ,week16,week40.
week4 ,week16,week40.
changes in HAD scale score compared with baseline
Time Frame: week4 ,week16,week40.
week4 ,week16,week40.
changes in self-esteem scale score compared with baseline
Time Frame: week4 ,week16,week40.
week4 ,week16,week40.
changes in serum total cholesterol compared with baseline
Time Frame: week16.
week16.
changes in serum triglyceride compared with baseline
Time Frame: week16.
week16.
changes in low-density lipoprotein cholesterol (LDL-C) compared with baseline
Time Frame: week16.
week16.
changes in High-density lipoprotein cholesterol(HDL-C) compared with baseline
Time Frame: week16.
week16.
changes in fasting blood-glucose （FBG）compared with baseline
Time Frame: week16.
week16.
changes in fasting insulin ( FINS) compared with baseline
Time Frame: week16.
week16.
The adverse effects of catgut implantation at acupoints and as measured by number of participants with adverse events.
Time Frame: from week 2 to week 16.
The adverse effects of catgut implantation at acupoints include local swelling, pruritus, fever, festering and unbearable pain. In the event of an adverse effect during the trial, the patient should immediately contact the physician. All adverse effects should be promptly recorded.
from week 2 to week 16.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hubei Hospital of Traditional Chinese Medicine

Collaborators

Dongzhimen Hospital, Beijing
State Administration of Traditional Chinese Medicine of the People's Republic of China
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2017

Primary Completion (Actual)

May 15, 2018

Study Completion (Actual)

May 15, 2018

Study Registration Dates

First Submitted

October 8, 2016

First Submitted That Met QC Criteria

October 14, 2016

First Posted (Estimate)

October 18, 2016

Study Record Updates

Last Update Posted (Actual)

December 5, 2019

Last Update Submitted That Met QC Criteria

December 3, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 201507003
  • ChiCTR-IOR-16008384 (Registry Identifier: A Multicenter Randomized Controlled Trial of Catgut Implantation at Acupoints for the Treatment of Simple Obesity)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

the data will be published in the form of public papers before May 2019 for public inquiries

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Real catgut implantation at acupoints

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe